决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors.
我们的数据表明,SB 转座子系统是对高功能 CAR NK 细胞进行非病毒工程改造的一种高效、安全且具成本效益的方法,可能适用于白血病以及许多其他恶性肿瘤的癌症免疫治疗。
自然杀伤(NK)细胞具有强大的内在细胞毒能力,临床试验已证明其用于癌症过继治疗的安全性和有效性。表达嵌合抗原受体(CAR)可提高 NK 细胞靶向特异性,并可使用异基因供者制成现货型产品。本研究首次提出一种创新 CAR-NK 工程化方法,采用非病毒 Sleeping Beauty(SB)转座子/转座酶系统和微型环状 DNA 载体。SB 改造的外周血原代 NK 细胞显示高且稳定的 CAR 表达,且相比慢病毒载体,更常将载体整合于基因组安全港位点。重要的是,SB 制备的 CAR-NK 较未转染 NK 细胞细胞毒性增强。体外以已建立的急性淋巴细胞白血病细胞以及患者来源原代急性 B 细胞白血病和淋巴瘤样本为靶细胞,并在异种移植白血病小鼠模型中进行体内验证,均证实其具有强效抗白血病潜力。数据提示,SB 转座子系统是一种高效、安全且经济的 CAR-NK 非病毒工程化方法,可能适用于白血病及其他多种恶性肿瘤免疫治疗。
Natural killer (NK) cells have high intrinsic cytotoxic capacity, and clinical trials have demonstrated their safety and efficacy for adoptive cancer therapy. Expression of chimeric antigen receptors (CARs) enhances NK cell target specificity, with these cells applicable as off-the-shelf products generated from allogeneic donors. Here, we present for the first time an innovative approach for CAR NK cell engineering employing a non-viral Sleeping Beauty (SB) transposon/transposase-based system and minimized DNA vectors termed minicircles. SB-modified peripheral blood-derived primary NK cells displayed high and stable CAR expression and more frequent vector integration into genomic safe harbors than lentiviral vectors. Importantly, SB-generated CAR NK cells demonstrated enhanced cytotoxicity compared with non-transfected NK cells. A strong antileukemic potential was confirmed using established acute lymphocytic leukemia cells and patient-derived primary acute B cell leukemia and lymphoma samples as targets in vitro and in vivo in a xenograft leukemia mouse model. Our data suggest that the SB-transposon system is an efficient, safe, and cost-effective approach to non-viral engineering of highly functional CAR NK cells, which may be suitable for cancer immunotherapy of leukemia as well as many other malignancies.
MEMBER ACCOUNT
登录成功会直接打开下一页。